Evidence comparison
Semaglutide vs Tirzepatide: How They Differ
A medically reviewed comparison of semaglutide and tirzepatide, including mechanisms, evidence, side effects, and questions to discuss with a clinician.
Medically Reviewed
Board-Certified OB-GYN, Hormone & Longevity Specialist — University of Texas
Reviewed 2026-08-21
Quick answer
Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors. Clinical trials generally show greater average weight loss with tirzepatide, but the appropriate option depends on indication, tolerability, access, medical history, and clinician supervision.
Key takeaways
- Tirzepatide targets GIP and GLP-1; semaglutide targets GLP-1.
- Average trial outcomes are not a guarantee for an individual.
- Tolerability, indication, access, and clinical history should guide the decision.
Mechanism and approved use
Semaglutide acts at the GLP-1 receptor. Tirzepatide acts at GIP and GLP-1 receptors. Both can reduce appetite and slow gastric emptying. Approval, indication, dose, and availability vary by product and country; discuss the specific prescription with a licensed clinician.
What the evidence says
Head-to-head trial evidence has reported greater average weight reduction with tirzepatide than semaglutide in adults with obesity, but averages do not predict an individual response. Trial populations, doses, follow-up, and adverse-event reporting matter when interpreting the difference.
Safety and monitoring
Both medicines can cause gastrointestinal symptoms and require gradual titration. A clinician should review contraindications, concurrent medicines, hydration, nutrition, gallbladder symptoms, and persistent or severe abdominal pain. Do not combine GLP-1 medicines without medical direction.
Related HormoneStacks resources
Frequently asked questions
Can semaglutide and tirzepatide be taken together?
They should not be combined unless a qualified clinician specifically directs and monitors the treatment. Both affect appetite, gastrointestinal motility, and glucose regulation.
Which has more evidence?
Semaglutide has extensive GLP-1 clinical-outcome evidence, while tirzepatide has strong trial evidence for weight and glucose outcomes. The relevant evidence depends on the condition being treated.
Sources and limitations
This educational page is not medical advice and does not replace an examination or individualized treatment plan. Review the underlying evidence and discuss decisions with a qualified clinician.